Morgan Stanley
LTRN icon

Morgan Stanley’s Lantern Pharma LTRN Stock Holding History

Morgan Stanley’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.67K Buy
639
+38
+6% +$111 ﹤0.01% 7348
2026
Q1 		$823 Hold
601
– – ﹤0.01% 7464
2025
Q4 		$1.82K Hold
601
– – ﹤0.01% 7264
2025
Q3 		$2.61K Hold
601
– – ﹤0.01% 7252
2025
Q2 		$1.9K Hold
601
– – ﹤0.01% 7234
2025
Q1 		$2.13K Hold
601
– – ﹤0.01% 7166
2024
Q4 		$1.92K Buy
601
+1
+0.2% +$3 ﹤0.01% 7204
2024
Q3 		$2.2K Hold
600
– – ﹤0.01% 7111
2024
Q2 		$2.8K Sell
600
-115
-16% -$692 ﹤0.01% 6999
2024
Q1 		$6.29K Buy
715
+115
+19% +$614 ﹤0.01% 6835
2023
Q4 		$2.57K Buy
+600
New +$2.12K ﹤0.01% 7001
2023
Q1 		– Sell
-289
Closed -$1.75K – 7786
2022
Q4 		$1.75K Sell
289
-5
-2% -$25 ﹤0.01% 7393
2022
Q3 		$1K Sell
294
-1,100
-79% -$5.91K ﹤0.01% 7579
2022
Q2 		$8K Sell
1,394
-11,507
-89% -$68.6K ﹤0.01% 7278
2022
Q1 		$92K Sell
12,901
-38,440
-75% -$257K ﹤0.01% 6359
2021
Q4 		$410K Buy
51,341
+3,413
+7% +$31.2K ﹤0.01% 5667
2021
Q3 		$535K Sell
47,928
-4,376
-8% -$56.6K ﹤0.01% 5453
2021
Q2 		$764K Buy
52,304
+1,602
+3% +$24.7K ﹤0.01% 5242
2021
Q1 		$920K Buy
50,702
+22,785
+82% +$399K ﹤0.01% 4777
2020
Q4 		$537K Buy
27,917
+6,533
+31% +$113K ﹤0.01% 5040
2020
Q3 		$403K Buy
+21,384
New +$309K ﹤0.01% 4739

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Morgan Stanley's LTRN Position: Q2 2026 in Review

Morgan Stanley increased its Lantern Pharma (LTRN) stake by 6.3% in Q2 2026, buying an estimated $111 and bringing the position to 639 shares worth $2.67K. The position accounts for ﹤0.01% of the portfolio, ranked #7348.

Morgan Stanley first reported a position in LTRN in Q3 2020 and has held it in 21 quarters since. The position peaked at $920K in Q1 2021. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Morgan Stanley held 639 shares of Lantern Pharma worth $2.67K as of Q2 2026.
  • Morgan Stanley bought 38 Lantern Pharma shares in Q2 2026, an estimated $111.
  • Lantern Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7348 holding.
  • Morgan Stanley first reported a position in Lantern Pharma in Q3 2020 and has held it in 21 quarters since.
  • Morgan Stanley's Lantern Pharma position peaked at $920K in Q1 2021.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.